Korean J Fam Pract 2020; 10(3): 164-175  https://doi.org/10.21215/kjfp.2020.10.3.164
The Pharmacologic Management of Chronic Non-Cancer Pain
Jin-Chul Lee*
Department of Interventional Pain Management Center, Daejeon Woori Hospital, Daejeon, Korea
Jin-Chul Lee
Tel: +82-42-829-0921, Fax: +82-42-478-9114
E-mail: jinjurry@naver.com
ORCID: http://orcid.org/0000-0002-8166-4794
Received: April 17, 2020; Revised: May 22, 2020; Accepted: May 24, 2020; Published online: June 20, 2020.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Chronic pain is defined as pain that persists for more than 3 months. While it is a common condition that affects an estimated 20% of the population worldwide, its management is generally unsatisfactory. Owing to its multidimensional and complex pathophysiology, a multi-modal approach is required to manage chronic pain. Pharmacologic therapy is an important treatment modality for this condition; however, in South Korea, pragmatic guidelines for chronic pain management are rarely published. Due to differences in the ethnicity and health-care settings, Western guidelines cannot be fully applied to South Korea. In the present study, new clinical evidences for chronic pain medications (acetaminophen, nonsteroidal antiinflammatory drugs, opioids, anticonvulsants, antidepressants, herbal agents, and so on) were reviewed and the pragmatic stepwise medication strategies for the following three common chronic pain conditions were developed: chronic musculoskeletal pain (caused by osteoarthritis), chronic musculoskeletal pain (caused by reasons other than osteoarthritis), and chronic neuropathic pain.
Keywords: Chronic Pain; Musculoskeletal Pain; Neuropathic Pain; Pain Medication; Analgesics
References
  1. van Hecke O, Torrance N, Smith BH. Chronic pain epidemiology and its clinical relevance. Br J Anaesth 2013; 111: 13-8.
    Pubmed CrossRef
  2. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain 2015; 156: 1003-7.
    Pubmed KoreaMed CrossRef
  3. Ernstzen DV, Louw QA, Hillier SL. Clinical practice guidelines for the management of chronic musculoskeletal pain in primary healthcare: a systematic review. Implement Sci 2017; 12: 1.
    Pubmed KoreaMed CrossRef
  4. Healthcare Improvement Scotland. SIGN 136 management of chronic pain:a national clinical guideline [Internet]. Edinburgh: SIGN; 2019 [cited 2020 Mar 15].
    Available from: https://www.sign.ac.uk/assets/sign136_2019.pdf
  5. Feinberg S, Mackey S, Aggarwal A, Barad M, Gregory N, David K, et al. Resource guide to chronic pain management [Internet]. Rocklin: American Chronic Pain Association; 2020 [cited 2020 Mar 15].
    Available from: https://www.theacpa.org/pain-management-tools/resource-guide-to-chronicpain-treatments/resource-guide-to-chronic-pain-management/
  6. Manchikanti L, Kaye AD, Falco FJE, Hirsch JA. Essentials of interventional techniques in managing chronic pain. Cham: Springer; 2018. p. 15-25.
    CrossRef
  7. Vadivelu N, Urman RD, Hines RL, Kunnumpurath S. Essentials of pain management. New York (NY): Springer; 2011. p. 17.
    CrossRef
  8. Dale R, Stacey B. Multimodal treatment of chronic pain. Med Clin North Am 2016; 100: 55-64.
    Pubmed CrossRef
  9. Cuomo A, Bimonte S, Forte CA, Botti G, Cascella M. Multimodal approaches and tailored therapies for pain management: the trolley analgesic model. J Pain Res 2019; 12: 711-4.
    Pubmed KoreaMed CrossRef
  10. Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: a metaanalysis of randomized controlled trials. Eur J Rheumatol 2017; 4: 11-8.
    Pubmed KoreaMed CrossRef
  11. National Institute for Health and Care Excellence. Management of osteoarthritis [Internet]. London: NICE; 2020 [cited 2020 Mar 15].
    Available from: https://pathways.nice.org.uk/pathways/osteoarthritis/management-ofosteoarthritis.pdf
  12. Brune K, Patrignani P. New insights into the use of currently available nonsteroidal anti-inflammatory drugs. J Pain Res 2015; 8: 105-18.
    Pubmed KoreaMed CrossRef
  13. Institute for Clinical Systems Improvement. Pain; assessment, non-opioid treatment approaches and opioid management [Internet]. Bloomington:ICSI; 2017 [cited 2020 Mar 15].
    Available from: https://www.icsi.org/guideline/pain/
  14. Fulton RL, Walters MR, Morton R, Touyz RM, Dominiczak AF, Morrison DS, et al. Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort. Hypertension 2015; 65: 1008-14.
    Pubmed CrossRef
  15. National Institute for Health and Care Excellence. Osteoarthritis: care and management [Internet]. London: NICE; 2014 [cited 2020 Mar 15].
    Available from: https://www.ncbi.nlm.nih.gov/books/NBK248069/pdf/Bookshelf_NBK248069.pdf
  16. Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, FourrierReglat A, Nicotra F, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35: 1127-46.
    Pubmed KoreaMed CrossRef
  17. Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016; 375: 2519-29.
    Pubmed CrossRef
  18. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015; 63:2227-46.
    Pubmed CrossRef
  19. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62: 1592-601.
    Pubmed CrossRef
  20. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123: 2226-35.
    Pubmed CrossRef
  21. Perry LA, Mosler C, Atkins A, Minehart M. Cardiovascular risk associated with NSAIDs and COX-2 inhibitors. US Pharm 2014; 39: 35-8.
  22. Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 2018; 67: 1042-51.
    Pubmed KoreaMed CrossRef
  23. Yoshizawa K, Kawai K, Fujie M, Suzuki J, Ogawa Y, Yajima T, et al. Overall safety profile and effectiveness of tramadol hydrochloride/acetaminophen in patients with chronic noncancer pain in Japanese real-world practice. Curr Med Res Opin 2015; 31: 2119-29.
    Pubmed CrossRef
  24. Vadivelu N, Huang Y, Mirante B, Jacoby M, Braveman FR, Hines RL, et al. Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthc Patient Saf 2013; 5: 151-9.
    Pubmed KoreaMed CrossRef
  25. Mercier F, Claret L, Prins K, Bruno R. A model-based meta-analysis to compare efficacy and tolerability of tramadol and tapentadol for the treatment of chronic non-malignant pain. Pain Ther 2014; 3: 31-44.
    Pubmed KoreaMed CrossRef
  26. Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician 2013; 16: 27-40.
    Pubmed
  27. Baron R, Likar R, Martin-Mola E, Blanco FJ, Kennes L, Müller M, et al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 study. Pain Pract 2016; 16: 580-99.
    Pubmed CrossRef
  28. Xiao JP, Li AL, Feng BM, Ye Y, Wang GJ. Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain: a systematic review and meta-analysis. Pain Med 2017; 18: 14-24.
    Pubmed CrossRef
  29. Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010; 11: 1787-804.
    Pubmed CrossRef
  30. Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010; 27: 381-99.
    Pubmed CrossRef
  31. Gálvez R, Schäfer M, Hans G, Falke D, Steigerwald I. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Adv Ther 2013; 30: 229-59.
    Pubmed CrossRef
  32. Santos J, Alarcão J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2015;2015: CD009923.
    Pubmed KoreaMed CrossRef
  33. Dart RC, Cicero TJ, Surratt HL, Rosenblum A, Bartelson BB, Adams EH. Assessment of the abuse of tapentadol immediate release: the first 24 months. J Opioid Manag 2012; 8: 395-402.
    Pubmed CrossRef
  34. Baron R, Martin-Mola E, Müller M, Dubois C, Falke D, Steigerwald I. Effectiveness and safety of tapentadol prolonged release (PR) versus a combination of tapentadol PR and pregabalin for the management of severe, chronic low back pain with a neuropathic component: a randomized, double-blind, phase 3b study. Pain Pract 2015; 15: 455-70.
    Pubmed CrossRef
  35. Steigerwald I, Schenk M, Lahne U, Gebuhr P, Falke D, Hoggart B. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin Drug Investig 2013; 33: 607-19.
    Pubmed KoreaMed CrossRef
  36. Wolff RF, Aune D, Truyers C, Hernandez AV, Misso K, Riemsma R, et al. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin 2012; 28: 833-45.
    Pubmed CrossRef
  37. Welsh C, Valadez-Meltzer A. Buprenorphine: a (relatively) new treatment for opioid dependence. Psychiatry (Edgmont) 2005; 2: 29-39.
    Pubmed KoreaMed
  38. Genova A, Dix O, Thakur M, Sangha PS. Chronic non-cancer pain management and addiction: a review. Cureus 2020; 12: e6963.
    CrossRef
  39. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf 2014; 5: 38-56.
    Pubmed KoreaMed CrossRef
  40. Hirakata M, Yoshida S, Tanaka-Mizuno S, Kuwauchi A, Kawakami K. Pregabalin prescription for neuropathic pain and fibromyalgia: a descriptive study using administrative database in Japan. Pain Res Manag 2018; 2018:2786151.
    Pubmed KoreaMed CrossRef
  41. Shim JH. Clinical application of α2-δ ligand. Hanyang Med Rev 2011; 31:55-62.
    CrossRef
  42. Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 2012; 29: 177-82.
    Pubmed CrossRef
  43. Pérez C, Navarro A, Saldaña MT, Masramón X, Rejas J. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study. Clin Ther 2010; 32: 1357-70.
    Pubmed CrossRef
  44. Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med 2010; 11: 456-65.
    Pubmed CrossRef
  45. Shaheen A, Alam SM, Ahmad A, Khan M. Clinical efficacy and tolerability of gabapentinoids with current prescription patterns in patients with neuropathic pain. Pak J Med Sci 2019; 35: 1505-10.
    Pubmed KoreaMed CrossRef
  46. Lee DK. Indication of antidepressants other than depression. Korean J Clin Geri 2015; 16: 8-16.
    CrossRef
  47. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015; 2015:CD008242.
    KoreaMed CrossRef
  48. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14: 162-73.
    CrossRef
  49. Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebocontrolled trial. Curr Med Res Opin 2011; 27: 2361-72.
    Pubmed CrossRef
  50. Citrome L, Weiss-Citrome A. A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Postgrad Med 2012; 124: 83-93.
    Pubmed CrossRef
  51. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; (1):CD007115.
    Pubmed CrossRef
  52. Skljarevski V, Zhang S, Desaiah D, Alaka KJ, Palacios S, Miazgowski T, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12week, fixed-dose, randomized, double-blind trial. J Pain 2010; 11: 1282-90.
    Pubmed CrossRef
  53. Choi JH, Choi JH, Kim DY, Yoon JH, Youn HY, Yi JB, et al. Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model. Osteoarthritis Cartilage 2002; 10: 471-8.
    Pubmed CrossRef
  54. Hartog A, Hougee S, Faber J, Sanders A, Zuurman C, Smit HF, et al. The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators. Phytomedicine 2008; 15: 313-20.
    Pubmed CrossRef
  55. Kim JH, Ryu KH, Jung KW, Han CK, Kwak WJ, Cho YB. SKI306X suppresses cartilage destruction and inhibits the production of matrix metalloproteinase in rabbit joint cartilage explant culture. J Pharmacol Sci 2005; 98:298-306.
    Pubmed CrossRef
  56. Kim JI, Choi JY, Kim KG, Lee MC. Efficacy of JOINS on cartilage protection in knee osteoarthritis: prospective randomized controlled trial. Knee Surg Relat Res 2017; 29: 217-24.
    Pubmed KoreaMed CrossRef
  57. Jung YB, Seong SC, Lee MC, Shin YU, Kim DH, Kim JM, et al. A four-week, randomized, double-blind trial of the efficacy and safety of SKI306X: a herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee. Am J Chin Med. 2004; 32: 291-301.
    Pubmed CrossRef
  58. Song YW, Lee EY, Koh EM, Cha HS, Yoo B, Lee CK, et al. Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. Clin Ther 2007; 29: 862-73.
    Pubmed CrossRef
  59. Jung YB, Roh KJ, Jung JA, Jung K, Yoo H, Cho YB, et al. Effect of SKI 306X, a new herbal anti-arthritic agent, in patients with osteoarthritis of the knee: a double-blind placebo controlled study. Am J Chin Med 2001; 29: 485-91.
    Pubmed CrossRef
  60. Woo Y, Hyun MK. Evaluation of cardiovascular risk associated with SKI306X use in patients with osteoarthritis and rheumatoid arthritis. J Ethnopharmacol 2017; 207: 42-6.
    Pubmed CrossRef
  61. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2012; 9: CD007400.
    Pubmed KoreaMed CrossRef

This Article


Author ORCID Information

Services
Social Network Service

e-submission

Archives